Integra expands its regenerative capabilities with ACell acquisition

 

• Integra LifeSciences (NASDAQ:IART) has agreed to acquire ACell, a regenerative medicine company with a product portfolio based on porcine urinary bladder matrix platform technology, MatriStem UBM. The acquisition will help the expansion of Integra’s Orthopedics and Tissue Technologies segment.
• Deal value includes an upfront cash payment of $300M, and up to an additional $100M upon the achievement of certain revenue growth milestones.
• The transaction is expected to close in Q1 of 2021.
• ACell’s products include MicroMatrix, a particulate formulation, as well as Cytal Wound Matrix and Gentrix Surgical Matrix, both sheet formulations for the management of acute and chronic wounds and reinforcement of soft tissue in certain surgical applications.
• In 2019, ACell generated revenues of $100.8M, +13% Y/Y. Integra expects this transaction to be accretive to revenue growth and adjusted gross margins.
• Integra will host a conference call today at 9AM E.T. to provide more information regarding the acquisition.
• Earlier this year, ACell filed a preliminary prospectus for an $86M IPO.
• https://seekingalpha.com/news/3644840-integra-lifesciences-expands-regenerative-capabilities-acell-acquisition